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Abstract: Renal hypoxia has recently been implicated as a key contributor and indicator of various
glomerular diseases. As such, monitoring changes in renal oxygenation in these disorders may
provide an early diagnostic advantage that could prevent potential adverse outcomes. Blood oxygen
level-dependent magnetic resonance imaging (BOLD MRI) is an emerging noninvasive technique for
assessing renal oxygenation in glomerular disease. Although BOLD MRI has produced promising
initial results for the use in certain renal pathologies, the use of BOLD imaging in glomerular diseases,
including primary and secondary nephrotic and nephritic syndromes, is relatively unexplored. Early
BOLD studies on primary nephrotic syndrome, nephrotic syndrome secondary to diabetes mellitus,
and nephritic syndrome secondary to systemic lupus erythematosus have shown promising results to
support its future clinical utility. In this review, we outline the advancements made in understanding
the use of BOLD MRI for the assessment, diagnosis, and screening of these pathologies.
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1. Introduction
Glomerular disease continues to be a large health burden worldwide, often occurring
as a primary process or as secondary to systemic inflammatory conditions, infections, and
diabetes mellitus [1]. In the past 10 years, multiple studies have implicated renal hypoxia
in glomerular disease [2–4]. These studies indicate that patients with glomerular disease
exhibit significant decreases in both renal blood flow and oxygenation, possibly due to
basement membrane thickening and extracellular collagen deposition in the mesangium [5].
In order to reduce potential adverse outcomes, monitoring renal hypoxia may establish an
early diagnosis and even help monitor disease progression. A novel noninvasive method
currently being investigated for such purposes is blood oxygenation level-dependent mag-
netic resonance imaging (BOLD MRI), a functional MRI (fMRI) technique that can evaluate
organ function on the basis of differences in the magnetic properties of deoxyhemoglobin
and hemoglobin. BOLD MRI operates by detecting the differing paramagnetic spin states of
deoxyhemoglobin versus oxyhemoglobin. Increasing amounts of deoxyhemoglobin induce
an internal magnetic field and phase dispersions of neighboring spin states, which ulti-
mately distorts the MRI signal. These results are reported as the R2* (sec−1) value, which is
the apparent relaxation rate and indicates the relative content of deoxyhemoglobin. Higher
R2* values are inversely correlated with tissue oxygenation and vice versa. For example,
tissue areas receiving increased blood flow have a decreased proportion of deoxygenated
hemoglobin, and thus, a lower apparent relaxation rate R2*.
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BOLD MRI has been a cornerstone in neuroimaging since the early 1990s, giving
clinicians the ability to measure areas of the brain affected by ischemia [6]. Neurologists
and neurosurgeons consistently employ BOLD as a primary fMRI technique, often using it
for pre-operative analysis as well as other applications such as seizure tracking [7]. Such
extensive use in neurology clinics, as well as in research, is responsible for most of our
current understanding of the best data acquisition methods for BOLD MRI. However, this
technological and scientific understanding is relatively specific to cerebrovascular imaging.
With the clear physiological differences between the brain and kidney, specific techniques
and settings for renal imaging are needed. This has led to the investigation of BOLD MRI’s
utility in renal disease, especially chronic kidney disease (CKD) and renal artery stenosis.
As both pathologies involve hypoxia, BOLD MRI may be an effective tool to track disease
progression [8]. Furthermore, these studies have found that for renal BOLD imaging, a
multiple gradient-recalled-echo (mGRE) sequence has a superior signal-to-noise ratio and
resolution compared to a spin-echo sequence [9]. These BOLD MRI results are commonly
analyzed using region of interest (ROI) analysis to assess medullary R2* (mR2*) and cortical
R2* (cR2*) values, giving physicians important insights into the respective oxygenation
of the kidney. Another method being investigated is the twelve-layer concentric objects
(TLCO) technique, which may have better accuracy than ROI analysis in advanced disease
(Figure 1) [10].
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makes it a highly attractive option for use in the clinical setting. Given that renal tissue 
hypoxia plays a major role in the development of primary and secondary glomerular dis-
ease, BOLD MRI could play an important role by allowing for earlier identification and 
initiation of treatment. As imaging does not currently play a significant role in the diag-
nosis or management of such diseases, BOLD MRI has the potential to change current 
clinical guidelines. Here, we review recent advances made in BOLD MRI’s use in primary 
nephrotic syndrome, secondary nephrotic syndrome due to diabetes mellitus, and sec-
ondary nephritic syndrome due to systemic lupus erythematosus (SLE). 
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Interestingly, e erging literature no indicates that B L RI can also be used for
glo erular disease diagnosis and management. In contrast to anatomical methods such as
sonography, BOLD MRI provides clinicians with a more effective ability to f ctio all
e al ate early changes in nephrotic and nephritic syndromes, encompassing both primary
and secondary etiologies. The capability to noninvasively assess renal oxygenation makes it
a highly attractive option for use in the clinical setting. Given that renal tissue hypoxia plays
a major ro e in the devel pment of primary a d second r glomerular disease, BOLD MRI
could play an important role by allowing for earlier identification and initiation of treatme t.
As maging does not currently play a sig ificant role in the dia osis or management of
such diseases, BOLD MRI has the potential to change curr nt cli ical guidelin s. Here,
we review r cent advances made in BOLD MRI’s use in primary nephrotic syndrome,
secondary neph tic syndrome due to diabetes mellitus, and secondary nephr ic syndrome
due to system c lupus erythematosus (SLE).
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2. Primary Nephrotic Syndrome
Primary nephrotic syndrome (PNS) is a collection of symptoms that result from
glomerular basement membrane damage, leading to shared features of proteinuria, hyper-
lipidemia, hypercoagulability, hypogammaglobulinemia, and hypoalbuminemia. Causes
of PNS include minimal change disease (MCD), membranous glomerulonephritis (MGN),
and focal segmental glomerulosclerosis (FSGS). Abnormal intrarenal oxygenation pat-
terns and consequent hypoxia associated with primary nephrotic syndrome have spurred
investigations into BOLD MRI’s use in these disorders.
As mentioned, medullary R2* values in BOLD MRI are used as a marker for medullary
oxygen concentration, with several studies correlating lower mR2* values with primary
nephrotic syndrome progression. Recent research showed that patients with various causes
of primary nephrotic syndrome had significantly lower mR2* values compared to controls.
Their mR2* values were also negatively correlated with estimated glomerular filtration rate
(eGFR) and positively correlated with tubulointerstitial lesions [11]. The significantly lower
mR2* seen in PNS patients may be secondary to reduced sodium reabsorption, and thus,
reduced oxygen consumption, as well as enhanced oxyhemoglobin concentrations within
inflammatory and immune-mediated kidney injuries [11–13]. Furthermore, correlations of
mR2* with eGFR highlight the potential for BOLD MRI to be used clinically in PNS patients
to evaluate their kidney function and prognosis [11,14].
Another recent study showed that higher cR2* values correlated positively with hy-
poxia and renal impairment in a sample of 29 patients with CKD, 9 of whom had underlying
membranous glomerulonephritis [5]. Given that these findings were in CKD patients, of
whom a large proportion had membranous glomerulonephritis, further investigation into
an isolated patient population of those with MGN or other PNS is warranted. Such studies
would help to support the use of BOLD MRI in the clinical setting for monitoring renal
function in patients with PNS.
3. Nephrotic Syndrome Secondary to Diabetes Mellitus
Uncontrolled diabetes mellitus can lead to diabetic nephropathy (DN), which can
later present as a secondary nephrotic syndrome. Development of nephrotic syndrome
in diabetic patients involves multiple mechanisms and signaling pathways, including
increased extracellular matrix deposition at the glomerular basement membrane. Long-
standing diabetic nephropathy can lead to persistent albuminuria that depletes serum
albumin, leading to edema and other classical symptoms of nephrotic syndrome [15]. The
increased prevalence of secondary nephrotic syndrome due to diabetes has made screening
for DN imperative. Testing for microalbuminuria has been a commonly used screening test
in diabetic patients, but several studies have demonstrated that microalbuminuria often
resolves in early stage DN patients and may not be an accurate biomarker [16–18]. While
the introduction of contiguous tests, such as albumin to creatinine ratios, has attempted
to increase the accuracy of screening and diagnosis, there is still room for innovation in
this constantly developing area. Such potential makes BOLD MRI a highly attractive
noninvasive alternative to evaluate DN progression.
To this end, several studies have attempted to correlate BOLD MRI results with
DN progression in order to monitor the disease before its development to nephrotic
syndrome (Figure 2). One BOLD MRI study found that mR2* values were highest in
diabetic patients with normoalbuminuria when compared to healthy patients and diabetic
patients with microalbuminuria, suggesting that medullary hypoxia may resolve with DN
progression [19]. These results are in contrast to another study by Wang et al., which found
that mR2* values in DN patients were significantly lower than those in healthy patients
(Figure 2) [20]. This discrepancy may be explained by the fact that advanced DN reduces the
glomerular filtration rate, in turn decreasing sodium transport and renal oxygen usage [20].
A higher kidney oxygenation (lower mR2* values) occurs as a result, which may reconcile
with the lower mR2* values found in Feng et al.’s moderately microalbuminuric patients.
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Figure 2. Representative BOLD MRI images of healthy and diabetic nephropathy patients. (a,b) 
Gradient-recalled-echo maps and R2* maps of a healthy patient, respectively. (c,d) Gradient-re-
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diabetic patient, indicating decreased mR2* values that result in reduced contrast. (Figure reprinted 
with permission from Wiley, from Wang et al., 2011). 
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Figure 2. Representative BOLD MRI images of healthy and diabetic nephropathy patients. (a,b)
Gradient-recalled-echo maps and R2* maps of a healthy patient, respectively. (c,d) Gradient-recalled-
echo maps and R2* maps of a patient with diabetic nephropathy, respectively. There is a greater degree
of contrast between the cortex and medulla of the healthy patient compared to the diabetic patient,
indicating decreased R2* values that result in reduced contrast. (Figure reprinted with permission
from Wiley, from Wang et al., 2011).
However, other studies that examine the impact of drugs on DN patients still use
lower mR2* values as an indicator of success. One study found that DN patients who
received lipo-prostaglandin E1 had significant decreases in mR2* values due to a reduction
in tissue hypoxia following 14 days of treatment, compared to no significant differences in
non-diabetic CKD patients [21]. Pruijm et al. administered angiotensin-converting enzyme
inhibitors and angiotensin II receptor blockers to patients with diabetic kidney disease to
explore the utility of BOLD MRI [22]. Unlike Li et al., they found that a renin–angiotensin–
aldosterone system (RAAS) blockade did not induce significant change in R2* values [22].
The authors suggested that hypoxia is not involved in early diabetic nephropathy, which
is in direct contrast to Feng et al.’s conclusions. Given the heterogeneity of results, more
studies are needed in order to fully explore the clinical use of BOLD MRI in assessment of
diabetic nephropathy progression.
4. Nephritic Syndrome Secondary to Systemic Lupus Erythematosus
Systemic lupus erythematosus (SLE) is a complex disease that can affect nearly every
organ syste in the b . e f t e ea liest a ifestations is lupus nephritis (LN),
a secondary glomerular disease th t affects more than 6 ,000 Americ s and is seen in
more than 30% of SLE patients [23,24]. SLE patients often und rgo frequent urinalysis,
including urine protein xcretion an sedimentatio , in o der to detect early manifes ations
of nephritis. An abnormal urinalysis raises suspicion f r guide a physician’s
decision to pursue a biopsy. Diagnosis and personalized treatment are often guided by
biopsy, which clas ifies renal involvement using the International Society of Nephrology
and the Renal Pathol gy Society (ISN/RPS) guidelines (Figure 3). LN can present as several
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different subtypes of both nephrotic and nephritic syndromes, and most commonly presents
as diffuse proliferative nephritis, a type of nephritic syndrome. For simplicity’s sake, we
grouped LN under secondary nephritic syndrome, as its most common manifestation is
diffuse proliferative glomerulonephritis, a nephritic syndrome. It is worth acknowledging
that LN can present as a nephrotic syndrome, and some of the following studies use a
patient sample that has a mixed population of LN subtypes.
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Unfortunately, tients undergo multiple biopsies n the years after diagnosis
in order to track the diseas r ression and monitor the r sponse to treatment, increasing
both the cost and inconvenience to the patient. This has driven the investigation into
BOLD MRI’s potential use for diagnosis and monitoring of lupus nephritis. Several early
landmark studies have shown promising results. Li et al. demonstrated that cR2* and mR2*
values were significantly lower in LN patients than in healthy controls [25]. In contrast,
two recent studies by Rapacci et al. and Shi et al. did not find significant associations
between cortical or medullary R2* values and the disease state [26,27]. This contrast
may be due to sample population differences, as a majority of Li et al.’s patients were
ISN/RPS Class III and ab ve. Noneth less, both Shi et al. and Li et al. found that the
degree of tubul interstitial lesions was negativ ly correlated with mR2* [25,27]. Giv n this
association and the fact that the degree of tubulointerstitial nephritis in LN is predictive of
poor outcomes, mR2* values from BOLD MRI could serve a clinical role in LN patients [28].
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5. Discussion
Although BOLD MRI was initially used for cerebrovascular imaging, its use in other
organ systems is being increasingly explored. Recent literature demonstrates that BOLD
MRI of the kidney has significant potential for clinical and research use (Table 1). Not
only is the technology noninvasive, but it also allows clinicians to image and function-
ally understand renal blood flow and oxygenation without using contrast or radiation.
Here, we explored advances made in understanding the technology underlying BOLD
MRI for renal studies as well as for its potential diagnostic and clinical role in several
nephrotic and nephritic syndromes. For diabetic patients, several studies used BOLD MRI
to evaluate diabetic nephropathy progression, but the correlation of R2* values with DN
stages yielded mixed results. Two studies that evaluated the effect of diabetic nephropathy
treatment on BOLD MRI values differed, finding that lipo-prostaglandin E1 decreased
mR2* levels, but that RAAS-modulating drugs did not [21,22]. These inconclusive results
demonstrate that more BOLD MRI studies on diabetic nephropathy are needed. In re-
gard to primary nephrotic syndrome, early research is supportive of BOLD MRI’s clinical
use, although further research that evaluates each nephrotic syndrome individually (e.g.,
MGN) is needed, rather than summative analyses. Given the association of nephrotic
syndrome with renal hypoxia and BOLD MRI’s utility in assessing intrarenal oxygenation,
this technology may serve a role in determining a patient-specific prognosis as well as
evaluating progression for those with PNS. Investigations into the utility of using BOLD
MRI in nephritic syndrome secondary to lupus nephritis showed promise, as two recent
studies found consistent and statistically significant correlations in the ability of BOLD
MRI to detect tubulointerstitial pathology in LN patients. This raises the possibility of
using the technology to track progression of tubulointerstitial lesions, or even playing a
role in establishing the diagnosis. As prognosis and disease physiology in LN can widely
differ based on ISN/RPS classification, studies with samples that are more proportionally
balanced in terms of disease histopathology are needed to increase validity.
Table 1. Summary of BOLD MRI studies. MG = membranous glomerulonephritis, PNS = primary nephrotic syndrome,
DN = diabetic nephropathy, LN = lupus nephritis, NAU = normal to mildly increased albuminuria, MAU = moderately
increased albuminuria, TR = repetition time, TE = echo time.
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a MAU values. NAU values are as follows: estimated glomerular filtration rate (eGFR) 102.02 ± 17.80 (mL/min/1.73m2), cR2* 16.43 ± 2.12
(msec−1), mR2 * 34.61 ± 3.39 (msec−1). b (msec−1).
Considering that lesions in the glomeruli are primarily in the renal cortex, monitoring
changes in cR2* values may appear more appropriate for BOLD imaging of glomerular
diseases. However, most studies report a greater statistical significance between mR2*
values and disease state compared to cR2* values and disease state. This may be explained
by two reasons: The renal medulla receives less blood perfusion compared to the renal
cortex, and sodium transporters in the renal medulla exert a high metabolic demand.
Pathologic decreases in blood perfusion may result in a lower blood oxygen content, which
is exacerbated by high oxygen consumption occurring in the medullary collecting ducts.
While the lesions in nephrotic and nephritic syndrome are primarily in the cortex, there
may be a pathologic downstream translation to the medulla, which could explain the high
medullary signal in the presented data.
Although many of the reported studies are promising, it is important to address
several limitations. First, BOLD MRI signals can be affected by factors such as temperature
and pH. For example, increased temperature increases oxygen offloading, shifting the
oxygenation dissociation curve to the right and causing changes in BOLD signal intensity,
independent of perfusion. These distinct influences on oxygen offloading can complicate
attempts to associate renal perfusion and BOLD MRI signals [9]. Furthermore, oxygenation,
blood flow, sodium transport, and hydration status are all interdependent and any external
or internal factors that influence those variables can create noise that interferes with BOLD
signals. It is important that these variables are controlled as best as possible prior to
proceeding with BOLD MRI, in both research studies and the clinic, for the standardization
of results [8,29,30]. Non-oxygenation-related interference factors within BOLD MRI must
also be addressed. For example, BOLD signal loss has been documented in neuroimaging,
stemming from metal implants such as intracortical electrodes [31]. In renal imaging, the
presence of nephrolithiasis or hip arthroplasty can limit visualization of target lesions.
Additionally, motion artifacts such as body movement, physiologic noise (such as pulsatile
cerebrospinal fluid and arterial blood), and instrumentation noise from scanners can cause
interference with BOLD signals [31,32].
MRIs are also expensive and time consuming, limiting the number of participants
enrolled in studies [5,11,26,27,29,33,34]. Larger sample sizes are necessary to validate
whether BOLD MRI is truly effective in the clinical assessment of renal function in patients
with glomerular disease; one study also recommended the use of multicenter randomized
controlled trials for external validity of the usage of BOLD MRI [33]. Variability and
limitations in imaging techniques within BOLD MRI also limit the internal validity. For
example, ROI analysis is commonly used, but is known to have relatively poor levels of
inter-observer reliability. Furthermore, in advanced stages of glomerular diseases, the renal
cortex and medulla are often difficult to visually distinguish, impairing visualization of the
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ROI. The use of the TLCO technique has been shown to produce a higher sensitivity and
specificity for BOLD imaging in advanced kidney diseases compared to ROI [35].
In conclusion, BOLD MRI has shown promising early results for potential use in
clinical practice. While the technology has significant limitations that must be considered,
numerous studies have shown encouraging findings that should be further investigated.
These advancements in BOLD MRI have the potential to significantly change diagnosis,
monitoring, and long-term outcomes of patients with glomerular disease.
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BOLD MRI Blood oxygen level-dependent magnetic resonance imaging
CKD Chronic kidney disease
DN Diabetic nephropathy
eGFR Estimated glomerular filtration rate
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LN Lupus nephritis
mGRE Multiple gradient-recalled-echo
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